Clinical response to chemotherapy in non-small cell lung carcinoma patients
DOI:
https://doi.org/10.18203/2320-6012.ijrms20195531Keywords:
Cancer, Lung, Patient, ResponseAbstract
Background: Lung carcinoma is the most common. With this, a study was conducted to assess the clinical profile of Non-small cell lung carcinoma (NSCLC) and also to evaluate the response to chemotherapy in various stages of NSCLC.
Methods: It was a prospective study. All the clinically confirmed cases with NSCLC were taken into consideration. Clinical staging was done, diagnosis was confirmed by histopathological findings. Treatment was given depending on the stage of carcinoma. Patients were evaluated before each cycle of chemotherapy for any progression of disease. Pathological response was evaluated after completion of 6 cycles of chemotherapy. Chi square test was used to find the statistical significance; p<0.05 was considered statistically significant.
Results: Total 153 patients admitted to oncology wing were taken to the study, with mean age 59.07±10.618 years, 2.6 male female ratio. In this 73% were in stage III and the remaining in stage IV NSCLC. Majority (56.10%) of the study subjects in stage III NSCLC showed partial response, Majority (68%) of the subjects in stage IV NSCLC showed partial response; the difference was Statistically significant (p<0.05).
Conclusions: NSCLS is common in older people with male dominance due to habits.
References
American cancer society lung cancer epidemiology. Available at: https://www.cancer.org/content/dam/ cancer-org/research/cancer-facts-and statistics/ annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf. Accessed 21 September 2019.
Indian council of Medical Research. National Cancer Registry Programme. Three year report of population based cancer registries: 2009 - 2011 Available at: http://www.ncepindia.org. Accessed 15 September 2019.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: Cancer J Clini. 2005;55(2):74-108.
Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175-80.
Standfield L, Weston AR, Barraclough H, Van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non‐small cell lung cancer: A systematic review of the evidence. Respirol. 2011;16(8):1210-20.
Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thoracic Oncol. 2011;6(1):64-70.
Valaitis J, Warren S, Gamble D. Increasing incidence of adenocarcinoma of the lung. Cancer. 1981;47(5):1042-6.
Janssen Heijnen ML, Corbergh JW. The changing epidemiologies of lung cancer in Europe. Lung Cancer. 2003;41(3):245-58.
Thun MJ, Henley SJ, Burns D, Jemal A, Shanks TG, Calle EE. Lung cancer death rates in lifelong nonsmokers. J Nat Cancer Inst. 2006;98(10):691-9.
Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA et al. Lung cancer incidence in never-smokers. J Clin Oncol: Offic J Am Soc Clini Oncol. 2007;25(5):472.
Stella GM, Luisetti M, Pozzi E, Comoglio PM. Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respirat Med. 2013;1(3):251-61.
Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J Clini Oncol. 2006;24(18 suppl):7082.
Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic Proceed. 2008;83(3):355-67.
Shaper AG, Wannamethee SG, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men. Intern J Epidemiol. 2003;32(5):802-8.
Henley SJ, Thun MJ, Chao A, Calle EE. Association between exclusive pipe smoking and mortality from cancer and other diseases. J Nat Cancer Inst. 2004;96(11):853-61.
Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. Thorax. 1996;51(6):564-8.
Miron L, Bosanceanu M, Filimon R, Petrariu FD. Clinical-epidemiological study on advanced non-small cell lung cancer. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2014;118(2):492-6.
Hsu LH, Chu NM, Liu CC, Tsai SY, You DL, KOJS, et al. Sex associated differences in non small cell lung carcinoma in the new era: is gender an independent prognostic factor. Lung Cancer 2009;66(2):262-7.
Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, et al. Phase II Multi centric trial with carboplatin and gemcitabine/ paclitaxel chemotherapy followed by radiotherapy concomitantly with low dose paclitaxel and gemcitabine for stage III A and III B non small cell lung carcinoma; J Thorac Oncol. 2007;2(10):927-32.
Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Onchol. 2008;13(1):5-13.
Akhtari M, Bernicker EH, Teh BS. Chemotherapy in non-small cell lung carcinoma: opportunities for advancement. Chin J Cancer 2016;35:56-61.
